연구성과로 돌아가기

2023 연구성과 (191 / 285)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
Article Comparison of a Non-Opioid Multimodal Analgesia Protocol with Opioid-Based Patient-Controlled Analgesia for Pain Control Following Robot-Assisted Radical Prostatectomy A Randomized, Non-Inferiority Trial Background: Opioid use after surgery is a potential contributor to the opioid epidemic. An adequate pain control method after surgery while minimizing opioid exposure is needed. This study aimed to compare the effect of non-opioid multimodal analgesia (NOMA) protocol with opioid-based patient-controlled analgesia (PCA) for pain relief after robot-assisted radical prostatectomy (RARP). Methods: This prospective randomized, open, non-inferiority trial included 80 patients scheduled for RARP. The NOMA group received pregabalin, paracetamol, bilateral quadratus lumborum block, and pudendal nerve block. PCA group received PCA. Pain scores, postoperative nausea and vomiting, opioid requirements, and quality of recovery were recorded 48 hours after surgery. Results: We found no significant differences in pain scores. The mean difference in pain score during rest at 24 h was 0.5 (95% CI -0.5 to 2.0). This result demonstrated the non-inferiority of NOMA protocol to PCA at our non-inferiority margin (-1). In addition, 23 patients in the NOMA group did not receive any opioid agonist for 48 h after surgery. Recovery of bowel function was also faster in the NOMA group than in the PCA group (25.0 hours vs 33.4 hours, p = 0.01). Limitations: We did not evaluate whether our NOMA protocol could decrease the incidence of new continuous opioid use after surgery. Conclusion: NOMA protocol successfully controlled postoperative pain and was non-inferior to morphine-based PCA regarding patient-reported pain intensity. It also promoted recovery of bowel function and decreased postoperative nausea and vomiting. Lee, Jeong Eun; Oh, Jinyoung; Lee, Jun Nyung; Ri, Hyun-Su; Lee, Chang Sub; Yeo, Jinseok Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Anesthesiol & Pain Med, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Urol, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Anesthesiol & Pain Med, Daegu, South Korea 57224846206; 57609999900; 16301364600; 42462457900; 58112015800; 35072322000 painfree@gmail.com; JOURNAL OF PAIN RESEARCH J PAIN RES 1178-7090 16 SCIE CLINICAL NEUROLOGY 2023 2.5 46.2 1.05 2025-06-25 4 4 multimodal analgesia; opioid sparing; postoperative pain; robot-assisted radical prostatectomy BLADDER DISCOMFORT; POSTOPERATIVE PAIN; CATHETER; PREGABALIN; MANAGEMENT; BLOCK; REMIFENTANIL; PARACETAMOL; PREVENTION; EFFICACY multimodal analgesia; opioid sparing; postoperative pain; robot-assisted radical prostatectomy desflurane; lidocaine; morphine; opiate; opiate agonist; paracetamol; pregabalin; propofol; remifentanil; rocuronium; ropivacaine; tramadol; adult; aged; analgesia; Article; bispectral index; human; major clinical study; muscle relaxation; nerve block; non-inferiority trial; patient controlled analgesia; postoperative nausea and vomiting; postoperative pain; prospective study; pudendal nerve; quadratus lumborum block; questionnaire; randomized controlled trial; robot-assisted prostatectomy; visual analog scale English 2023 2023 10.2147/jpr.s397529 바로가기 바로가기 바로가기 바로가기
Article Caudal pulmonary artery to vein ratio on radiography can predict pulmonary hypertension in dogs with mitral regurgitation Pulmonary hypertension (PH) is an important predictor of poor outcomes in dogs with mitral regurgitation (MR). The feasibility of radiography to predict PH in dogs with MR is unknown. This retrospective, observational, and analytic study aimed to identify a radiographic parameter to predict PH in dogs with MR. A total of 302 dogs diagnosed with MR on echocardiography were enrolled. Medical record and radiographic findings such as the size of the main pulmonary artery, left atrium, left ventricle, and right chamber, and cranial and caudal pulmonary arteries and veins were evaluated according to the presence of PH. The diameters of the cranial and caudal pulmonary vessels were compared to the fourth rib and the ninth rib, respectively, and the ratio of the pulmonary artery to the corresponding vein (CdPA/CdPV) was calculated. Pulmonary hypertension was diagnosed in 77 dogs (25.5%) and the prevalence of PH increased with MR grade. The CdPA/CdPV was significantly higher (P < 0.001) in the presence of PH. Multivariate analysis showed that the CdPA/CdPV was the only independent radiographic parameter that had a significant association with PH in dogs with MR (P = 0.028). The cut-off value of the CdPA/CdPV = 1.10 showed 90.6% specificity and 31.1% sensitivity for detecting PH in dogs with MR. In dogs with MR, PH can be predicted with high specificity when the caudal pulmonary artery is 1.1 times larger than the corresponding vein on radiographs. Lee, Sang-Kwon; Choi, Jihye Kyungpook Natl Univ, Coll Vet Med, Daegu 41566, South Korea; Seoul Natl Univ, Coll Vet Med, Seoul 08826, South Korea 56494541400; 7501393193 imsono@snu.ac.kr; VETERINARY RADIOLOGY & ULTRASOUND VET RADIOL ULTRASOUN 1058-8183 1740-8261 64 1 SCIE VETERINARY SCIENCES 2023 1.3 46.4 0.74 2025-06-25 2 2 canine; myxomatous mitral valve disease; pressure of pulmonary artery; tricuspid regurgitation; X-ray DOPPLER-ECHOCARDIOGRAPHY; DIAGNOSTIC-VALUE; DIAMETER canine; myxomatous mitral valve disease; pressure of pulmonary artery; tricuspid regurgitation; X-ray Animals; Dog Diseases; Dogs; Hypertension, Pulmonary; Mitral Valve Insufficiency; Pulmonary Artery; Radiography; Retrospective Studies; analysis of variance; analytic method; animal experiment; Article; blood pressure; body weight; castrated female; castrated male; caudal pulmonary artery; disease severity; dog; Doppler echocardiography; echocardiography; female; heart left atrium; heart left ventricle; hypertrophic cardiomyopathy; lung blood vessel; male; medical record; medical record review; mitral valve regurgitation; multivariate analysis; nonhuman; observational study; prediction; pressure gradient; prevalence; pulmonary artery; pulmonary hypertension; radiographic parameter; radiography; retrospective study; rib; sensitivity and specificity; thorax radiography; vein; animal; complication; diagnostic imaging; dog; dog disease; mitral valve regurgitation; pulmonary artery; pulmonary hypertension; radiography; veterinary medicine English 2023 2023-01 10.1111/vru.13145 바로가기 바로가기 바로가기 바로가기
Article Computed tomography can differentiate vaginal-origin from uterine-origin lesions in bitches OBJECTIVETo investigate typical computed tomography (CT) features for the differentiation of vaginal from the uterine origin in dogs.ANIMALS7 healthy Beagles in the prospective study and 5 bitches in the retrospective study.PROCEDURESIn the prospective study, dual-phase CT images were obtained from sexually intact female Beagles (n = 7) during anestrus and estrus. On the CT images, the vagina and uterine horns, body, and cervix were assessed for diameter, attenuation, and contrast enhancement pattern. In the retrospective study, CT features of large vaginal lesions (leiomyoma, leiomyosarcoma, adenocarcinoma, hematocolpos, and Gartner's duct cyst) were assessed in 5 bitches.RESULTSIn normal bitches, the cervix was thicker with strong central enhancement compared to the uterus and vagina. The uterine artery, which enters the mesometrium at the level of the cervix, was clearly visualized and assisted in iden-tifying the cervix. In bitches with large vaginal masses, uterine arteries were displaced by the lesions and could not be used to locate the cervix. In 4/5 dogs with vaginal masses, identification of the cervix allowed the determination of the organ of origin. In 1 dog with adenocarcinoma, CT vaginography was additionally required for determining the origin of mass.CLINICAL RELEVANCEResults from this study indicate that the cervix, recognized in CT as focal thickening of the uterus with central enhancement, may be used as a landmark for the differentiation between the uterus and vagina in bitches. Jung, Jin-Woo; Lee, Eunji; Kim, Soyeon; Park, Seungjo; Lee, Sang-kwon; Hong, Sunghwa; Choi, Jihye Chonnam Natl Univ, Coll Vet Med, Dept Vet Med Imaging, Gwangju, South Korea; Kyungpook Natl Univ, Coll Vet Med, Dept Vet Med Imaging, Daegu, South Korea; Helix Anim Med Ctr, Dept Vet Diagnost Imaging, Seoul, South Korea; Seoul Natl Univ, Coll Vet Med, Dept Vet Med Imaging, Seoul, South Korea 57215052035; 57225178262; 56643583100; 55944920400; 56494541400; 59601614100; 7501393193 imsono@snu.ac.kr; AMERICAN JOURNAL OF VETERINARY RESEARCH AM J VET RES 0002-9645 1943-5681 84 1 SCIE VETERINARY SCIENCES 2023 1.3 46.4 1.1 2025-06-25 3 3 VESTIBULOVAGINAL STENOSIS; ESTROUS-CYCLE; DOGS Adenocarcinoma; Animals; Dogs; Female; Prospective Studies; Retrospective Studies; Tomography, X-Ray Computed; Uterus; Vagina; iohexol; medetomidine; tiletamine plus zolazepam; zolazepam; adenocarcinoma; Article; beagle; bitch; computer assisted tomography; cytology; dog; echography; female; hematocolpos; histopathology; leiomyoma; leiomyosarcoma; nonhuman; physical examination; retrospective study; urethra injury; uterus horn; vagina smear; vaginal injury; adenocarcinoma; animal; diagnostic imaging; dog; prospective study; uterus; vagina; veterinary medicine; x-ray computed tomography English 2023 2023-01 10.2460/ajvr.22.03.0052 바로가기 바로가기 바로가기 바로가기
Article Deep learning-based reconstruction can improve canine thoracolumbar magnetic resonance image quality and reduce slice thickness In veterinary practice, thin-sliced thoracolumbar MRI is useful in detecting small lesions, especially in small-breed dogs. However, it is challenging due to the partial volume averaging effect and increase in scan time. Currently, deep learning-based reconstruction (DLR), a part of artificial intelligence, has been applied in diagnostic imaging. We hypothesized that the diagnostic performance of thin-slice thoracolumbar MRI with DLR would be superior to conventional MRI. This prospective, method comparison study aimed to determine the adequate slice thickness of a deep learning model for thin-slice thoracolumbar MRI. Sagittal and transverse T2-weighted MRI at the thoracolumbar region were performed on 12 clinically healthy beagle dogs; the images obtained were categorized into five groups according to slice thickness: conventional thickness of 3 mm (3CON) and thicknesses of 3, 2, 1.5, and 1 mm with DLR (3DLR, 2DLR, 1.5DLR, and 1DLR, respectively). Quantitative analysis was performed using signal-to-noise ratio (SNR) and contrast-to-noise ratio. Qualitative analysis involved the evaluation of perceived SNR, structural visibility, and overall image quality using a four-point scale. Moreover, nerve root visibility was evaluated using transverse images. Quantitative and qualitative values were compared among the five groups. Compared with the 3CON group, the 3DLR, 2DLR, and 1.5DLR groups exhibited significantly higher quantitative and qualitative values. Nerve root visibility was significantly higher in 2DLR, 1.5DLR, and 1DLR images than in 3DLR and 3CON images. Compared with conventional MRI, DLR reduced the slice thickness by up to one-half and improved image quality in this sample of clinically healthy beagles. Kang, Hyesun; Noh, Daji; Lee, Sang-Kwon; Choi, Sooyoung; Lee, Kija Kyungpook Natl Univ, Coll Vet Med, Daegu, South Korea; Kangwon Natl Univ, Coll Vet Med, Chuncheon Si, South Korea; Kyungpook Natl Univ, Coll Vet Med, 80 Daehak Ro, Daegu 41566, South Korea Lee, Sang-Kwon/IYI-9991-2023 57578843200; 57188552722; 56494541400; 55736574600; 35311016000 leekj@knu.ac.kr; VETERINARY RADIOLOGY & ULTRASOUND VET RADIOL ULTRASOUN 1058-8183 1740-8261 64 6 SCIE VETERINARY SCIENCES 2023 1.3 46.4 0.37 2025-06-25 1 1 artificial intelligence; dog; magnetic resonance imaging; thin-slice; vertebrae SPINAL-CORD; DOGS; SEQUENCE; DISEASE; MRI artificial intelligence; dog; magnetic resonance imaging; thin-slice; vertebrae Animals; Artificial Intelligence; Deep Learning; Dogs; Magnetic Resonance Imaging; Prospective Studies; Radiation Dosage; Radiographic Image Interpretation, Computer-Assisted; Signal-To-Noise Ratio; article; artificial intelligence; beagle; clinical article; contrast to noise ratio; controlled study; deep learning; diagnostic test accuracy study; diagnostic value; dog; human; human experiment; image quality; nerve root; nonhuman; nuclear magnetic resonance imaging; prospective study; qualitative analysis; quantitative analysis; signal noise ratio; T2 weighted imaging; thickness; three-dimensional imaging; vertebra; visibility; animal; computer assisted diagnosis; dog; nuclear magnetic resonance imaging; radiation dose; veterinary medicine English 2023 2023-11 10.1111/vru.13298 바로가기 바로가기 바로가기 바로가기
Article Deep learning-based reconstruction for canine brain magnetic resonance imaging could improve image quality while reducing scan time Optimal magnetic resonance imaging (MRI) quality and shorter scan time are challenging to achieve in veterinary practices. Recently, deep learning-based reconstruction (DLR) has been proposed for ideal image quality. We hypothesized that DLR-based MRI will improve brain imaging quality and reduce scan time. This prospective, methods comparison study compared the MR image denoising performances of DLR and conventional methods, with the aim of reducing scan time and improving canine brain image quality. Transverse T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences of the brain were performed in 12 clinically healthy beagle dogs. Different numbers of excitations (NEX) were used to obtain the image groups NEX4, NEX2, and NEX1. DLR was applied to NEX2 and NEX1 to obtain NEX2(DL) and NEX1(DL). The scan times were recorded, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were calculated for quantitative analysis. Five blinded veterinarians assessed the overall quality, contrast, and perceived SNR on four-point Likert scales. Quantitative and qualitative values were compared among the five groups. Compared with NEX4, NEX2 and NEX1 reduced scan time by 50% and 75%, respectively. The mean SNR and CNR of NEX2(DL) and NEX1(DL) were significantly superior to those of NEX4, NEX2, and NEX1 (P < 0.05). In all image quality indices, DLR-applied images for both T2-weighted and FLAIR images were significantly higher than NEX4 and NEX2(DL) had significantly better quality than NEX1(DL) for FLAIR (P < 0.05). Findings indicated that DLR reduced scan time and improved image quality compared with conventional MRI images in a sample of clinically healthy beagles. Choi, Hyejoon; Lee, Sang-Kwon; Choi, Hojung; Lee, Youngwon; Lee, Kija Kyungpook Natl Univ, Coll Vet Med, Daegu, South Korea; Chungnam Natl Univ, Coll Vet Med, Daejeon, South Korea; Kyungpook Natl Univ, Coll Vet Med, 80 Daehak Ro, Daegu 41566, South Korea Lee, Sang-Kwon/IYI-9991-2023 57578394700; 56494541400; 35202930200; 8983566800; 35311016000 leekj@knu.ac.kr; VETERINARY RADIOLOGY & ULTRASOUND VET RADIOL ULTRASOUN 1058-8183 1740-8261 64 5 SCIE VETERINARY SCIENCES 2023 1.3 46.4 1.1 2025-06-25 3 3 deep learning; denoising; dog; magnetic resonance imaging; neuroimaging MRI deep learning; denoising; dog; magnetic resonance imaging; neuroimaging Animals; Brain; Deep Learning; Dogs; Magnetic Resonance Imaging; Prospective Studies; Signal-To-Noise Ratio; article; beagle; brain; clinical article; contrast to noise ratio; controlled study; deep learning; dog; excitation; fluid-attenuated inversion recovery imaging; human; human experiment; image quality; Likert scale; neuroimaging; nonhuman; nuclear magnetic resonance imaging; prospective study; quantitative analysis; signal noise ratio; veterinarian; animal; brain; diagnostic imaging; dog; nuclear magnetic resonance imaging; pathology; procedures; veterinary medicine English 2023 2023-09 10.1111/vru.13279 바로가기 바로가기 바로가기 바로가기
Article Efficacy of androstenone in reducing stress- or fear-related responses of horses during riding Androstenone, which derived from boar pheromones, known as an interomone, has been documented to change behavior in dogs and horses. It could be a potential candidate for use in pheromonal therapy in horses. This study aimed to investigate the effect of androstenone treatment for improving the safety of horseback riding by reducing undesirable behavior of horses. In this study, fourteen horses were participated in a series of behavior tests with one rider to determine the effects of androstenone on behaviors. First, in the riding test without obstacles, the riding session lasted for 30 minutes with 5 minutes of walking, 10 minutes of trotting, 10 minutes of cantering, and 5 minutes of walking. The frequency of undesirable behavior during the riding sessions was monitored. Second, in the riding test with obstacles, the time to pass through from start line to finish line through an obstacle course was recorded. The course was organized with three consecutive blue tarps. Both tests used a cross-over design with 20 mu g of androstenone. In the riding test without obstacles, horses exhibited a significantly reduced frequency of undesirable behavior when treated with androstenone (P < 0.05). During obstacle course test, the horses completed the course faster under the influence of androstenone (P < 0.05). The placebo treatment did not result in a significant behavioral change in either test. These preliminary findings, limited by the small number of horses and the rider, warrant further invesgitation to substantiate the efficacy of androstenone for pheromonal therapy in equine practices. (c) 2023 Elsevier Inc. All rights reserved. Choi, Yeonju; Yoon, Minjung Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, Sangju, South Korea; Kyungpook Natl Univ, Dept Horse Compan & Wild Anim Sci, Sangju 742711, South Korea; Kyungpook Natl Univ, Res Ctr Horse Ind, Sangju, South Korea 57208551604; 22137296500 mjyoonemail@gmail.com; JOURNAL OF VETERINARY BEHAVIOR-CLINICAL APPLICATIONS AND RESEARCH J VET BEHAV 1558-7878 1878-7517 69 SCIE BEHAVIORAL SCIENCES;VETERINARY SCIENCES 2023 1.3 46.4 0 2025-06-25 0 0 Androstenone; Behavior; Horse; Horseback riding APPEASING PHEROMONE; LEARNING-THEORY; KICK INJURIES; BEHAVIOR; TEMPERAMENT; SEROTONIN; OXYTOCIN; GENES Androstenone; Behavior; Horse; Horseback riding androstenone; pheromone; placebo; unclassified drug; adult; animal behavior; animal experiment; Article; behavior assessment; behavior change; controlled study; fear; female; Haflinger horse; Halla horse; horse; horse breed; horseback riding; human; nonhuman; physiological stress; Thoroughbred horse; walking English 2023 2023-11 10.1016/j.jveb.2023.10.002 바로가기 바로가기 바로가기 바로가기
Article Increased radiographic opacity in the region of the gallbladder can be identified in dogs with large amounts of gallbladder sediment, sludge balls, and gallbladder mucocele Increased soft-tissue opacity in the region of the canine gallbladder is incidentally detected on radiographs. We hypothesized that there is a difference in the detection of gallbladder sediment on radiographs depending on the amount or mobility of the sediment. In this retrospective and analytical study, we aimed to assess the ultrasonographic features of gallbladder sediment that were detected radiographically. We also aimed to assess the differences in the detection of increased opacity of the gallbladder between radiographic views. We included 223 dogs that underwent thoracic radiography, abdominal radiography, and gallbladder ultrasonography. Ultrasonographic images of the gallbladder were divided into five groups: group 1, gravity-dependent sediment occupying = 50%; group 3, sediment attached to the gallbladder wall; group 4, sludge ball; and group 5, gallbladder mucocele. Dogs showing increased opacity on subjective assessment of any radiographic view were recorded, and the sensitivity of radiographic views for detecting gallbladder sediment was analyzed. Of 168 dogs with gallbladder sediment, 37 had increased opacity on at least one radiographic projection. The frequency was compared as a percentage within each category, and Group 4 was the highest percentage with increased radiographic gallbladder opacity, followed by Groups 2 and 5. The sensitivity for detecting increased opacity was highest in the thoracic ventrodorsal view. Thus, in dogs with increased gallbladder opacity on radiographs, large amounts of gallbladder sediment, sludge balls, and gallbladder mucocele should be considered differential diagnoses. In addition, the thoracic ventrodorsal view is recommended to evaluate gallbladder opacity. Jang, Hyunyoung; Lee, Sang-Kwon; Choi, Sooyoung; Choi, Hojung; Lee, Youngwon; Lee, Kija Kyungpook Natl Univ, Coll Vet Med, Daegu, South Korea; Kangwon Natl Univ, Coll Vet Med, Chunchon, South Korea; Chungnam Natl Univ, Coll Vet Med, Daejeon, South Korea; Kyungpook Natl Univ, Coll Vet Med, 80 Daehak Ro, Daegu 41566, South Korea ; Lee, Sang-Kwon/IYI-9991-2023 57311536900; 56494541400; 55736574600; 35202930200; 8983566800; 35311016000 leekj@knu.ac.kr; VETERINARY RADIOLOGY & ULTRASOUND VET RADIOL ULTRASOUN 1058-8183 1740-8261 64 4 SCIE VETERINARY SCIENCES 2023 1.3 46.4 0.37 2025-06-25 1 1 gallbladder materials; radiography; sensitivity; ultrasonography CLINICAL FINDINGS; ULTRASONOGRAPHY; DISEASES gallbladder materials; radiography; sensitivity; ultrasonography Animals; Dog Diseases; Dogs; Gallbladder; Gallbladder Diseases; Mucocele; Retrospective Studies; Sewage; Ultrasonography; abdominal radiography; animal experiment; Article; biliary sludge; cholelithiasis; dog; echography; gallbladder; gallbladder mucocele; gallbladder sediment; gallbladder wall; mucocele; nonhuman; radiography; retrospective study; sludge ball; thorax radiography; urine sediment; animal; diagnostic imaging; dog disease; gallbladder disease; sewage; veterinary medicine English 2023 2023-07 10.1111/vru.13233 바로가기 바로가기 바로가기 바로가기
Article Sex differences in the relationship between aggression and symptoms of depression and anxiety in adults with refractory focal epilepsy Purpose: To determine whether sex affects the relationship between aggression and symptoms of depression and anxiety in adults with refractory focal epilepsy. Methods: This cross-sectional study was conducted in 85 adults with refractory focal seizures, which are defined as one or more seizures recurring per month even when the patient is treated with two or more antiseizure medications. We used the Buss-Perry Aggression Questionnaire (AQ) and the Hospital Anxiety and Depression Scale (HADS) to evaluate aggression and symptoms of depression and anxiety, respectively. We performed multivariate linear regression and analysis of covariance with interaction terms. HADS-depression and HADS-anxiety scores were separately evaluated to avoid multicollinearity between both of them. Results: The HADS-depression and HADS-anxiety scores, male sex, an antiseizure medication load of >= 3, and the use of pregabalin were independently correlated with at least one of the AQ total and subscale scores. These models for depressive and anxiety symptoms explained 34.2% and 32.5%, respectively, of the variance of the AQ total score. Although the AQ total scores did not differ between the sexes, sex significantly affected the relationships between aggression and symptoms of depression and anxiety. Specifically, HADS-depression and HADS-anxiety scores were positively associated with the AQ total scores, especially scores of verbal aggression and anger subtypes, in men but not in women. Conclusions: These findings support the importance of including anger management and other strategies targeted toward aggression in the development of psychological interventions to reduce anxiety and depression in adults with refractory focal epilepsy. Tailoring those interventions to the needs of males and females will be important to consider. . Lee, Sang-Ahm; Jung, Mina; Im, Kayeong; Choi, Eun Ju; Jeon, Ji-Ye; Kim, Hyun-Woo; Koo, Yong Seo Univ Ulsan, Asan Med Ctr, Dept Neurol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Neurol, Yangsan, South Korea; Asan Med Ctr, Dept Neurol, 88 Olympic Ro 43 Gil, Seoul 138736, South Korea Lee, Dong/J-2778-2012; Koo, Yong/K-3468-2014; Choi, Eunju/IUO-8098-2023 57190211641; 57218659922; 57203142989; 56309158700; 57194943660; 57226027023; 35389057800 salee@amc.seoul.kr; EPILEPSY & BEHAVIOR EPILEPSY BEHAV 1525-5050 1525-5069 138 SCIE BEHAVIORAL SCIENCES;CLINICAL NEUROLOGY;PSYCHIATRY 2023 2.3 46.4 0.58 2025-06-25 3 3 Epilepsy; Refractory focal seizures; Aggression; Depression; Anxiety; Sex difference ANTIEPILEPTIC DRUGS; PREVALENCE; INSOMNIA; BEHAVIOR; PEOPLE Aggression; Anxiety; Depression; Epilepsy; Refractory focal seizures; Sex difference Adult; Aggression; Anxiety; Cross-Sectional Studies; Depression; Drug Resistant Epilepsy; Epilepsies, Partial; Female; Humans; Male; Seizures; Sex Characteristics; carbamazepine; lamotrigine; levetiracetam; lorazepam; oxcarbazepine; pregabalin; topiramate; valproic acid; zonisamide; adult; aggression; analysis of covariance; anger; anger management therapy; anxiety disorder; Article; Buss-Perry aggression questionnaire; central nervous system infection; controlled study; cross-sectional study; depression; disease duration; epilepsy; female; focal epilepsy; hippocampal sclerosis; Hospital Anxiety and Depression Scale; Hospital Anxiety and Depression Scale-Anxiety; Hospital Anxiety and Depression Scale-Depression; human; linear regression analysis; major clinical study; male; onset age; questionnaire; refractory focal epilepsy; seizure; self report; sex difference; verbal hostility; aggression; anxiety; complication; depression; drug resistant epilepsy; focal epilepsy; psychology; seizure; sexual characteristics English 2023 2023-01 10.1016/j.yebeh.2022.108983 바로가기 바로가기 바로가기 바로가기
Article A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Background We evaluated the therapeutic efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification.Methods This study was a multicenter, open-label, single-arm phase II trial. Recurrent GBM patients with EGFR amplification were eligible: EGFR amplification was determined using fluorescence in situ hybridization analysis when a sample had both the EGFR/CEP7 ratio of = 2 and a tight cluster EGFR signal in = 10% of recorded cells. GC1118 was administered intravenously at a dose of 4 mg/kg once weekly. The primary endpoint was the 6-month progression-free survival rate (PFS6). Next-generation sequencing was performed to investigate the molecular biomarkers related to the response to GC1118.Results Between April 2018 and December 2020, 21 patients were enrolled in the study and received GC1118 treatment. Eighteen patients were eligible for efficacy analysis. The PFS6 was 5.6% (95% confidence interval, 0.3%-25.8%, Wilson method). The median progression-free survival was 1.7 months (range: 28 days-7.2 months) and median overall survival was 5.7 months (range: 2-22.0 months). GC1118 was well tolerated except skin toxicities. Skin rash was the most frequent adverse event and four patients experienced Grade 3 skin-related toxicity. Genomic analysis revealed that the immune-related signatures were upregulated in patients with tumor regression.Conclusion This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune-mediated antitumor efficacy of GC1118. Choi, Seung Won; Jung, Hyun Ae; Cho, Hee-Jin; Kim, Tae Min; Park, Chul-Kee; Nam, Do-Hyun; Lee, Se-Hoon Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, 81 Irwon Ro, Seoul 06351, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 81 Irwon Ro, Seoul 06351, South Korea; Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Dept Internal Med, Seoul, South Korea; Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea ; Park, Chul-Kee/J-5499-2012; Kim, Tae/B-9921-2013 57193525550; 35272249400; 55937716400; 56510497300; 56424318200; 57190971869; 58376934900 nsnam@ssku.edu;sehoon.lee@samsung.com; CANCER MEDICINE CANCER MED-US 2045-7634 12 15 SCIE ONCOLOGY 2023 2.9 46.7 1.73 2025-06-25 12 11 EGFR; glioblastoma; immune response; monoclonal antibody DOUBLE-BLIND; BEVACIZUMAB; CETUXIMAB; TEMOZOLOMIDE; COMBINATION; LOMUSTINE; MUTATIONS; EFFICACY; GENES EGFR; glioblastoma; immune response; monoclonal antibody Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Chronic Disease; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Neoplasm Recurrence, Local; antineoplastic agent; depatuxizumab mafodotin; epidermal growth factor receptor antibody; gc1118; monoclonal antibody; RNA; unclassified drug; antineoplastic agent; GC1118; monoclonal antibody; acne; adult; aged; anorexia; antineoplastic activity; Article; clinical article; controlled study; diarrhea; drug efficacy; drug tolerability; dry skin; fatigue; female; fluorescence in situ hybridization; gene amplification; genetic analysis; glioblastoma; high throughput sequencing; human; immune response; life expectancy; maculopapular rash; male; missense mutation; multicenter study; nausea; oral mucositis; overall survival; phase 2 clinical trial; progression free survival; rash; RNA sequencing; skin toxicity; somatic mutation; therapy; treatment response; tumor growth; tumor regression; vomiting; whole exome sequencing; brain tumor; chronic disease; clinical trial; genetics; glioblastoma; tumor recurrence English 2023 2023-08 10.1002/cam4.6213 바로가기 바로가기 바로가기 바로가기
Article Jujuboside B post-treatment attenuates PM2.5-induced lung injury in mice Fine particulate matter (PM2.5) is an air pollutant that causes severe lung injury. We investigated the effects of Jujuboside B (JB), a component of Zizyphi Spinosi Semen, on lung toxicity caused by PM2.5, and we identified the mechanism of its protective effect. Lung injury in an animal model was induced by intratracheal administration of a PM2.5 suspension. After 2 days of PM2.5 pretreatment, mice were administered JB via the tail vein three times over a 2-day period. JB significantly reduced the histological lung damage as well as the lung wet/dry weight ratio. JB also considerably reduced PM2.5-induced autophagy dysfunction, apoptosis, inflammatory cytokine levels, and the number of PM2.5-induced lymphocytes in the bronchial alveolar fluid. We conclude that by regulating TLR2, 4-MyD88, and mTOR-autophagy pathways, JB exerts a protective effect on lung injury. Thus, JB can be used as a potential therapeutic agent for PM2.5-induced lung damage. Ryu, Soo Ho; Kim, Nayeon; Kim, Chaeyeong; Bae, Jong-Sup Kyungpook Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Daegu, South Korea Bae, Jong-Sup/AAU-9724-2020 baejs@knu.ac.kr; INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH INT J ENVIRON HEAL R 0960-3123 1369-1619 33 12 SCIE ENVIRONMENTAL SCIENCES;PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 2023 2.2 46.7 3 Jujuboside B; particulate matter; lung toxicity; TLR2; 4-MyD88 FINE PARTICULATE MATTER; INDUCED INFLAMMATION; IN-VITRO; PM2.5; AUTOPHAGY; MTOR; ACTIVATION; APOPTOSIS; EXPRESSION; POLLUTION English 2023 2023-12-02 10.1080/09603123.2022.2102156 바로가기 바로가기 바로가기
Article Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample OBJECTIVES: We estimated the population prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including unreported infections, through a Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) in 258 communities throughout Korea.METHODS: In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling. During face-to-face household interviews, participants self-reported their health status, COVID-19 diagnosis and vaccination history, and general characteristics. Subsequently, participants visited a community health center or medical clinic for blood sampling. Blood samples were analyzed for the presence of antibodies to spike proteins (anti-S) and antibodies to nucleocapsid proteins (anti-N) SARS-CoV-2 proteins using an electrochemiluminescence immunoassay. To estimate the population prevalence, the PROC SURVEYMEANS statistical procedure was employed, with weighting to reflect demographic data from July 2022.RESULTS: In total, 9,945 individuals from 5,041 households were surveyed across 258 communities, representing all basic local governments in Korea. The overall population-adjusted prevalence rates of anti-S and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency has reported a cumulative incidence of confirmed cases of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%.CONCLUSIONS: The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported cases existed. Furthermore, this study lays the foundation for a surveillance system to continuously monitor transmission at the community level and the response to COVID-19. Han, Jina; Baek, Hye Jin; Noh, Eunbi; Yoon, Kyuhyun; Kim, Jung Ae; Ryu, Sukhyun; Lee, Kay O.; Park, No Yai; Jung, Eunok; Kim, Sangil; Lee, Hyukmin; Hwang, Yoo-Sung; Jung, Jaehun; Lee, Hun Jae; Cho, Sung-il; Oh, Sangcheol; Kim, Migyeong; Oh, Chang-Mo; Yu, Byengchul; Hong, Young-Seoub; Kim, Keonyeop; Jung, Sunjae; Han, Mi Ah; Lee, Moo-Sik; Lee, Jung-Jeung; Hwangbo, Young; Yim, Hyeon Woo; Kim, Yu-Mi; Lee, Joongyub; Lee, Weon-Young; Park, Jae-Hyun; Oh, Sungsoo; Jo, Heui Sug; Kim, Hyeongsu; Kang, Gilwon; Nam, Hae-Sung; Lee, Ju-Hyung; Oh, Gyung-Jae; Shin, Min-Ho; Ryu, Soyeon; Hwang, Tae-Yoon; Park, Soon-Woo; Kim, Sang Kyu; Seol, Roma; Park, Ki-Soo; Kim, Su Young; Kwon, Jun-wook; Kim, Sung Soon; Kim, Byoungguk; Lee, June-Woo; Jang, Eun Young; Kim, Ah-Ra; Nam, Jeonghyun; Lee, Soon Young; Kim, Dong-Hyun Ajou Univ, Sch Med, Dept Prevent Med & Publ Hlth, 206 World Cup Ro, Suwon 16499, South Korea; Korea Inst Radiol & Med Sci, Natl Radiat Emergency Med Ctr, Seoul, South Korea; Seoul Natl Univ, Inst Hlth & Environm, Seoul, South Korea; Kyungmin Univ, Dept Nursing, Uijongbu, South Korea; Konyang Univ, Coll Med, Dept Prevent Med, Daejeon, South Korea; Gallup Korea, Seoul, South Korea; Inje Univ, Grad Sch Publ Hlth, Seoul, South Korea; Konkuk Univ, Dept Math, Seoul, South Korea; Catholic Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea; Seegene Med Fdn, Seoul, South Korea; Gachon Univ, Coll Med, Dept Prevent Med, Incheon, South Korea; Inha Univ, Dept Social & Prevent Med, Coll Med, Incheon, South Korea; Seoul Natl Univ, Grad Sch Publ Hlth, Dept Publ Hlth Sci, Seoul, South Korea; MAPO Gu Publ Hlth Ctr, Seoul, South Korea; GUNPO Si Publ Hlth Ctr, Gunpo, South Korea; Kyung Hee Univ, Sch Med, Dept Prevent Med, Seoul, South Korea; Kosin Univ, Coll Med, Dept Prevent Med, Busan, South Korea; Dong A Univ, Coll Med, Dept Prevent Med, Busan, South Korea; Kyungpook Natl Univ, Sch Med, Dept Prevent Med, Daegu, South Korea; Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Chosun Univ, Coll Med, Dept Prevent Med, Gwangju, South Korea; Keimyung Univ, Sch Med, Dept Prevent Med, Daegu, South Korea; Soonchunhyang Univ, Coll Med, Dept Prevent Med, Cheonan, South Korea; Catholic Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Hanyang Univ, Sch Publ Hlth, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Seoul Natl Univ, Inst Hlth Policy & Management, Med Res Ctr, Seoul, South Korea; Chung Ang Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Sungkyunkwan Univ, Dept Prevent Med, Sch Med, Suwon, South Korea; Yonsei Univ, Wonju Coll Med, Dept Occupat & Environm Med, Wonju, South Korea; Kangwon Natl Univ, Sch Med, Dept Hlth Policy & Management, Gangwon, South Korea; Konkuk Univ, Sch Med, Dept Prevent Med, Seoul, South Korea; Chungbuk Natl Univ, Coll Med, Dept Hlth Informat & Management, Cheongju, South Korea; Chungnam Natl Univ, Coll Med, Dept Prevent Med, Daejeon, South Korea; Jeonbuk Natl Univ, Dept Prevent Med, Med Sch, Jeonju, South Korea; Wonkwang Univ, Sch Med, Dept Prevent Med, Iksan, South Korea; Chonnam Natl Univ, Dept Prevent Med, Med Sch, Hwasun, South Korea; Yeungnam Univ, Coll Med, Dept Prevent Med & Publ Hlth, Gyongsan, South Korea; Daegu Catholic Univ, Sch Med, Dept Prevent Med, Gyongsan, South Korea; Dongguk Univ, Dept Prevent Med, Coll Med, Gyeongju, South Korea; Inje Univ, Coll Med, Dept Prevent Med, Busan, South Korea; Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Prevent Med, Jinju, South Korea; Jeju Natl Univ, Sch Med, Dept Prevent Med, Jeju, South Korea; Korea Dis Control & Prevent Agcy, Natl Inst Hlth, Cheongju, South Korea; Korea Dis Control & Prevent Agcy, Natl Inst Infect Dis, Ctr Vaccine Res, Cheongju, South Korea; Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res, Cheongju, South Korea; Hallym Univ, Coll Med, Dept Social & Prevent Med, 1 Hallymdaehak Gil, Chunchon 24252, South Korea Lee, Dae Young/ADO-9686-2022; Kim, Woo/D-2733-2015; Kim, Yu-Mi/AAU-5083-2021; Baek, Hye/AAC-7595-2020; Jung, Sun Jae/D-5620-2011; Kim, Suhnggwon/J-5407-2012; Lee, Sang-Jun/A-3892-2015; Ryu, Sukhyun/L-2706-2019; Kim, Dong/I-7600-2015; Kim, Sang-Kyu/ABE-9135-2020; JUNG, JAEHUN/KHE-5939-2024; Jung, Sun/O-5372-2019 58262777500; 58676568200; 57220181361; 56336586400; 58565360000; 57203497905; 58676509100; 57193435164; 7202854548; 58305384100; 8872234300; 58189870000; 56009790200; 54932347000; 56812499700; 58676544500; 58676509200; 36446549300; 24172894800; 35069534100; 35076059600; 57219165481; 56504367800; 57218160714; 57203144778; 55926551700; 7005664933; 36925270900; 36196796600; 35750156900; 57211913586; 35765888300; 7005809256; 57218412665; 55268382300; 7102066169; 7601476476; 7007056685; 7401537616; 9243360300; 13403059400; 14021980900; 27167894600; 58026582000; 56014252100; 57835471000; 55430140800; 57218856689; 57792610600; 56537158800; 57196067707; 57222144793; 54795525100; 56180604200; 57221405393; 58923343300; 58922060200; 59448852700; 59104736900; 59291679400; 58922910700; 58923132400; 59045546200; 59448705200; 59083457200; 58922478400; 59109568500; 58098304400; 59056617800; 58922910800; 59461196700; 59869639500; 58922269700; 58922478500; 58922060400; 59064926500; 58923343400; 58563529000; 59605126700; 58922689500; 58923558300; 58923558400; 58922060500; 58922269800; 59081508100; 57348252100; 58632774600 solee5301@gmail.com;dhkims@hallym.ac.kr; EPIDEMIOLOGY AND HEALTH EPIDEMIOL HEALTH 2092-7193 45 SCIE PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 2023 2.2 46.7 1.69 2025-06-25 8 8 COVID-19; Seroepidemiologic studies; Antibody; Community Health Survey; Sampling studies NUTRITION EXAMINATION SURVEY; UNITED-STATES; HEALTH; INFECTION Antibody; Community Health Survey; COVID-19; Sampling studies; Seroepidemiologic studies Antibodies, Viral; COVID-19; COVID-19 Testing; Humans; Republic of Korea; SARS-CoV-2; Seroepidemiologic Studies; guanine nucleotide binding protein; nucleocapsid protein; SARS-CoV-2 antibody; SARS-CoV-2 vaccine; vitronectin; virus antibody; adolescent; adult; aged; Article; blood sampling; child; coronavirus disease 2019; cumulative incidence; disease transmission; female; health care planning; health center; health status; health survey; household; household income; human; interdisciplinary research; interview; Korea; major clinical study; male; middle aged; prevalence; primary school; seroepidemiology; seroprevalence; vaccination; coronavirus disease 2019; COVID-19 testing; Severe acute respiratory syndrome coronavirus 2; South Korea English 2023 2023-08-17 10.4178/epih.e2023075 바로가기 바로가기 바로가기 바로가기
Article Regional disparities in major cancer incidence in Korea, 1999-2018 OBJECTIVES: This study investigated regional disparities in the incidence of 8 major cancers at the municipal level in Korea during 1999-2018 and evaluated the presence or absence of hot spots of cancer clusters during 2014-2018. METHODS: The Korea National Cancer Incidence Database was used. Age-standardized incidence rates were calculated by gender and region at the municipal level for 4 periods of 5 years and 8 cancer types. Regional disparities were calculated as both absolute and relative measures. The possibility of clusters was examined using global Moran’s I with a spatial weight matrix based on adjacency or distance. RESULTS: Regional disparities varied depending on cancer type and gender during the 20-year study period. For men, the regional disparities of stomach, colon and rectum, lung, and liver cancer declined, and those of thyroid and prostate cancer recently decreased, despite an overall increasing incidence. For women, regional disparities in stomach, colon and rectum, lung, liver, and cervical cancer declined, that of thyroid cancer recently decreased, despite an overall increasing incidence, and that of breast cancer steadily increased. In 2014-2018, breast cancer (I, 0.61; 95% confidence interval [CI], 0.53 to 0.70) showed a high probability of cancer clusters in women, and liver cancer (I, 0.48; 95% CI, 0.40 to 0.56) showed a high probability of cancer clusters in men. CONCLUSIONS: Disparities in cancer incidence that were not seen at the national level were discovered at the municipal level. These results could provide important directions for planning and implementing local cancer policies. © 2023 Korean Society of Epidemiology. All rights reserved. Park, Eun Hye; Kang, Mee Joo; Jung, Kyu-Won; Yun, E. Hwa; Kim, Hye-Jin; Kong, Hyun-Joo; Choi, Chang Kyun; Im, Jeong-Soo; Seo, Hong Gwan; Kim, Chang-Hoon; Yoo, Cheol-In; Kim, Yong-Dae; Kim, Young-Taek; Park, Chul Min; Youm, Jung-Ho; Lim, Kyuhyoung; Hong, Nam-Soo; Kweon, Sun-Seog; Kim, Woo-Chul; Park, Ki-Soo Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea, Graduate School of Public Health, Seoul National University, Seoul, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, South Korea; National Cancer Control Institute, National Cancer Center, Goyang, South Korea; Korea Central Cancer Registry, National Cancer Center, Goyang, South Korea, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea; Busan Cancer Registry, Pusan National University Hospital, South Korea; Ulsan Cancer Registry, Ulsan University Hospital, South Korea; Chungbuk Cancer Registry, Chungbuk National University Hospital, South Korea; Daejeon/Chungnam Cancer Registry, Chungnam National University and Hospital, South Korea; Jeju Cancer Registry, Jeju National University, and Hospital, South Korea; Jeonbuk Cancer Registry, Jeonbuk National University Hospital, South Korea; Kangwon Cancer Registry, Kangwon National University Hospital, South Korea; Daegu/Gyeongbuk Cancer Registry, Kyungpook National University Medical Center, South Korea; Gwangju/Jeonnam Cancer Registry, Chonnam National University Hwasun Hospital, South Korea; Incheon Cancer Registry, Inha University Hospital, South Korea; Gyeongnam Cancer Registry, Gyeongsang National University and Hospital, South Korea 56260883400; 23018377700; 7402479862; 35730464200; 57194054637; 57202469400; 57202957287; 14621582000; 57199873685; 57203626040; 7201746392; 8277138500; 57211411051; 57200324105; 58406928700; 24177182600; 54684167600; 7003824608; 55730056400; 56014252100 ara@ncc.re.kr; Epidemiology and Health EPIDEMIOL HEALTH 2092-7193 2092-7193 45 SCIE PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 2023 2.2 46.7 0.42 2025-06-25 2 Epidemiology; Incidence; Korea; Neoplasms; Small-area analysis Breast Neoplasms; Child, Preschool; Female; Humans; Incidence; Liver Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Republic of Korea; aged; Article; breast cancer; cancer incidence; colon cancer; controlled study; female; health care disparity; human; incidence; Korea; liver cancer; lung cancer; major clinical study; male; prostate cancer; rectum cancer; stomach cancer; thyroid cancer; breast tumor; liver tumor; neoplasm; preschool child; prostate tumor; South Korea English Final 2023 10.4178/epih.e2023089 바로가기 바로가기 바로가기
Article Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06 Background: Extramammary Paget's disease (EMPD) is rare. There are no standard treatments due to its rarity and few clinical trials. Methods: The objective of this multicenter study was to investigate treatment outcomes of Korean patients with advanced/metastatic EMPD. Data were collected retrospectively from 14 institutions participating in Korean Cancer Study Group (KCSG) Rare Cancer Committee. Results: A total of 37 patients were identified. Of these 37 patients, 6 received locoregional therapy as a first-line treatment. In 31 patients who received systemic chemotherapy as a first-line treatment, platinum-based chemotherapy (n = 22) achieved an objective response rate (ORR) of 45.5% and a median progression-free survival (PFS) of 7.89 months. Taxane-based chemotherapy (n = 8) achieved an objective response rate of 62.5% and median PFS of 9.73 months. In second-line chemotherapy, platinum-based chemotherapy (n = 4) had a disease control rate (DCR) of 75.0% and median PFS of 3.45 months. Taxane-based chemotherapy (n = 8) had a DCR of 75.0% and a median PFS of 8.67 months. Six patients received anti-human epidermal growth factor receptor 2 (HER2) antibody during first-and second-line chemotherapy. Overall, systemic chemotherapy combined with anti-HER2 antibody had an ORR of 100% and a median PFS of 13.31 months. The ORR and PFS with systemic chemotherapy combined with trastuzumab was better than platinum-and taxane-based chemotherapy only. Conclusions: Due to its rarity, advanced or metastatic EMPD still has no established standard treatment. Results of our study indicate that the combination of trastuzumab with taxane has longer survival than trastuzumab monotherapy or conventional platinum-or taxane-based chemotherapy. Sohn, Byeong Seok; Kim, Jeongeun; Kim, Miso; Hong, Jung Yong; Lee, Jieun; Park, Song Ee; Kim, Hyojeong; Lee, Hyo Jin; Kang, Eun Joo; Lee, Soon Il; Lee, In Hee; Huh, Seok Jae; Jo, Jeongmin; Kim, Ho Young Inje Univ, Sanggye Paik Hosp, Dept Internal Med, Coll Med, 1342 Dongilro, Seoul 01757, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Med Oncol, Seoul, South Korea; Chung Ang Univ, Dept Med, Div Hematol Oncol, Coll Med, Seoul, South Korea; Pusan Natl Univ, Dept Internal Med, Div Hematooncol, Sch Med, Busan, South Korea; Chungnam Natl Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Daejeon, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Hematol Oncol,Guro Hosp, Seoul, South Korea; Dankook Univ, Dept Internal Med, Div Hematol Oncol, Coll Med, Cheonan, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Oncol Hematol, Daegu, South Korea; Dong A Univ, Dept Internal Med, Coll Med, Busan, South Korea; Ewha Womans Univ, Dept Hematol Oncol, Med Ctr, Seoul, South Korea; Hallym Univ, Hallym Univ Sacred Heart Hosp, Dept Hematol Oncol, Coll Med, Anyang Si, South Korea Kim, Yun Hak/ABF-3331-2021; LEE, Sunghee/HCH-4510-2022; Lee, In/J-9324-2013; JY, LEE/GRS-9767-2022; kim, jong-eun/B-3550-2017; Kim, Ho-Young/HTR-7982-2023 17137510400; 57218595065; 55193756000; 57212848586; 58067353600; 57200152302; 57200111630; 57357625700; 57205231979; 55716345500; 57191881516; 43861285100; 57205525407; 57221442234 imbs@paik.ac.kr; CANCER MEDICINE CANCER MED-US 2045-7634 12 14 SCIE ONCOLOGY 2023 2.9 46.7 0.86 2025-06-25 4 5 chemotherapy; metastatic extramammary Paget's disease; overall survival; progression-free survival; trastuzumab PACLITAXEL; MAMMARY; CHEMOTHERAPY; MULTICENTER; MANAGEMENT; THERAPY chemotherapy; metastatic extramammary Paget's disease; overall survival; progression-free survival; trastuzumab Antineoplastic Combined Chemotherapy Protocols; Humans; Paget Disease, Extramammary; Receptor, ErbB-2; Republic of Korea; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; capecitabine; cisplatin; gemcitabine; paclitaxel; trastuzumab; antineoplastic agent; epidermal growth factor receptor 2; taxane; taxoid; trastuzumab; adult; advanced cancer; aged; Article; cancer chemotherapy; cancer control; clinical article; clinical effectiveness; clinical feature; drug effect; drug efficacy; drug mechanism; drug response; female; follow up; human; Korean (people); male; monotherapy; multicenter study; overall survival; Paget nipple disease; progression free survival; retrospective study; risk factor; survival rate; treatment outcome; clinical trial; Paget skin disease; South Korea; treatment outcome English 2023 2023-07 10.1002/cam4.6190 바로가기 바로가기 바로가기 바로가기
Article A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05% emulsion CsA twice daily in dry eye disease.Methods: 178 patients with dry eye disease were randomly assigned to one of two groups: the TJO-087 or CsA0.05% group. Changes in the Ocular Surface Disease Index (OSDI), tear film break-up time (TBUT), corneal and conjunctival staining scores, and Schirmer test scores from baseline to the 32-week visit were compared between both groups. To evaluate ocular tolerability of the study formulations, 7 symptoms (stinging/burning, itching, blurred vision, sandiness/grittiness, dryness, light sensitivity, and pain or soreness) were evaluated (the higher the score, the lower the tolerability) at each follow-up visit.Results: A total of 155 eyes of 155 patients were enrolled. The TJO-087 and CsA0.05% groups showed significant improvement in OSDI, TBUT, ocular surface staining, and Schirmer test scores at 32 weeks from baseline. There was no difference in the extent of improvement in all efficacy parameters. There were no differences in the ocular tolerability scores between the 2 groups at all visits, except that the itching score was higher in the TJO-087 group than in the CsA0.05% group at week 8.Conclusions: Using topical 0.08% CsA once daily is an effective therapeutic option for improving the symptoms and signs in dry eye disease, with a tolerability comparable with that of conventional 0.05% CsA. This trial was registered at the US National Library of Medicine ClinicalTrials.gov (http://clinicaltrial.gov) as NCT05245604 (registration date: 19/06/2020). Eom, Youngsub; Yoon, Kyung Chul; Kim, Hong Kyun; Song, Jong Suk; Hyon, Joon Young; Kim, Hyo Myung Korea Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea; Korea Univ, Ansan Hosp, Dept Ophthalmol, Seoul, Gyeonggido, South Korea; Chonnam Natl Univ, Med Sch, Dept Ophthalmol, Gwangju, South Korea; Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea; Korea Univ, Guro Hosp, Dept Ophthalmol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seongnam, South Korea; Korea Univ, Anam Hosp, Dept Ophthalmol, Seoul, South Korea; Korea Univ, Anam Hosp, Dept Ophthalmol, 73,Inchon ro, Seoul 02841, South Korea , James/ABG-8160-2020; Hyon, Joon/J-5720-2012 55504436000; 7401607582; 57218260940; 7404786554; 6507588001; 57877893300 hyomkim@kumc.or.kr; JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS J OCUL PHARMACOL TH 1080-7683 1557-7732 39 1 SCIE OPHTHALMOLOGY;PHARMACOLOGY & PHARMACY 2023 1.9 46.8 1.56 2025-06-25 6 7 cyclosporine A; randomized controlled study; dry eye diseases; efficacy; eye drops CATIONIC EMULSION; NATIONAL-HEALTH; LISSAMINE GREEN; RISK-FACTORS; DISEASE; GLAUCOMA; SAFETY; FLUORESCEIN; PREVALENCE cyclosporine A; dry eye diseases; efficacy; eye drops; randomized controlled study Conjunctiva; Cornea; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Pain; Tears; agents acting on the eye; artificial tear; cyclosporine; immunosuppressive agent; tjo 087; unclassified drug; cyclosporine; eye drops; adult; aged; Article; blurred vision; burning sensation; case control study; comparative effectiveness; conjunctival hemorrhage; conjunctival hyperemia; conjunctivitis; controlled study; corneal and conjunctival staining score; disease severity; double blind procedure; drug efficacy; drug formulation; drug safety; drug tolerability; dry eye; efficacy parameters; episcleritis; eye disease assessment; eye pain; eyelid disease; eyelid myokymia; female; follow up; human; keratitis; major clinical study; male; medication compliance; multicenter study; myokymia; nanoemulsion; Ocular Surface Disease Index; parallel design; patient compliance; photophobia; presbyopia; prospective study; pruritus; randomized controlled trial; Schirmer test; scleritis; side effect; South Korean; tear break-up time; therapy effect; topical treatment; clinical trial; conjunctiva; cornea; dry eye; lacrimal fluid; pain English 2023 2023-02-01 10.1089/jop.2022.0119 바로가기 바로가기 바로가기 바로가기
Article Adsorption of As and Pb by Stone Powder/Chitosan/Maghemite Composite Beads (SCM Beads): Kinetics and Column Study Adsorption kinetics of As and Pb onto composite beads synthesized with stone powder, chitosan, and maghemite (SCM beads) with weight ratio of 1:1:0.5 were investigated in batch mode. Several kinetic models such as pseudo-first order kinetic model (PFOKM), pseudo-second order kinetic model (PSOKM), two compartment first order kinetic model (TCFOKM), and modified two compartment first order kinetic model (MTCFOKM) were utilized to analyze the kinetics. Although the beads had low specific surface area and pore volume, MTCFOKM, one of two compartment models, could predict the most accurately because the As and Pb were adsorbed onto at least two kinds of adsorption sites such as functional groups in chitosan and Fe in maghemite. In MTCFOKM, both the fast adsorption fraction (f(1)') and the fast adsorption constant (k(1)') for Pb were higher than those for As. Therefore, the equilibrium time (t(eq)) for Pb adsorption was shorter than that for As adsorption, indicating that Pb adsorption was more affinitive than As adsorption onto SCM beads (especially maghemite). Column study with a bed column reactor packed with the SCM beads was also conducted. For column study, the effect of flow rate and pore volume on removal efficiency of As and Pb was also investigated. Three models such as the Thomas, Adams-Bohart (A-B), and Yoon-Nelson (Y-N) models were used to fit the column experimental data to analyze the breakthrough curves and the saturation time. Both Thomas and Y-N models were most appropriate. Conclusively, the SCM beads are suitable for adsorption treatment of As and Pb from contaminated groundwater and are particularly effective in Pb removal. Song, Gunho; Oh, Sanghwa Kyungpook Natl Univ, Sch Architectural Civil Environm & Energy Engn, Daegu 41566, South Korea 57210997152; 26665620700 shoh@knu.ac.kr; PROCESSES PROCESSES 2227-9717 11 2 SCIE ENGINEERING, CHEMICAL 2023 2.8 46.8 0.54 2025-06-25 3 4 arsenic; lead; SCM bead; adsorption kinetics; column study DESORPTION-KINETICS; AQUEOUS-SOLUTION; REMOVAL; SORPTION; LEAD; WATER; NANOPARTICLES; EQUILIBRIUM; GOETHITE; BIOMASS adsorption kinetics; arsenic; column study; lead; SCM bead Adsorption; Arsenic; Chemicals removal (water treatment); Groundwater; Groundwater pollution; Kinetic parameters; Kinetic theory; Adsorption kinetics; Column study; Composite beads; First-order kinetic models; Kinetic study; Maghemites; Pb adsorptions; Pore volume; Stone powder/chitosan/maghemite composite bead; Stone powders; Chitosan English 2023 2023-02 10.3390/pr11020581 바로가기 바로가기 바로가기 바로가기
페이지 이동:

논문 데이터 용어 설명

용어 설명
WoS Web of Science. Clarivate Analytics에서 제공하는 학술 데이터베이스입니다. 해당 논문이 WoS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
SCOPUS Elsevier에서 제공하는 세계 최대 규모의 초록 및 인용 데이터베이스입니다. 해당 논문이 SCOPUS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
Document Type 문헌의 유형을 나타냅니다. Article(원저), Review(리뷰), Proceeding Paper(학회논문), Editorial Material(편집자료), Letter(레터) 등으로 분류됩니다.
Title 논문의 제목입니다.
Abstract 논문의 초록(요약)입니다. 연구의 목적, 방법, 결과, 결론을 간략히 요약한 내용입니다.
Authors 논문의 저자 목록입니다. 공동 저자가 여러 명인 경우 세미콜론(;)으로 구분됩니다.
Affiliation 저자들의 소속 기관 정보입니다. 대학, 연구소, 기업 등 저자가 소속된 기관명이 표시됩니다.
ResearcherID (WoS) Web of Science의 고유 연구자 식별번호입니다. 동명이인을 구분하고 연구자의 업적을 정확하게 추적할 수 있습니다.
AuthorsID (SCOPUS) SCOPUS의 고유 저자 식별번호입니다. 연구자의 모든 출판물을 추적하고 관리하는 데 사용됩니다.
Journal 논문이 게재된 학술지의 정식 명칭입니다.
JCR Abbreviation Journal Citation Reports에서 사용하는 저널의 공식 약어입니다. 저널을 간략하게 표기할 때 사용됩니다.
ISSN International Standard Serial Number. 국제표준연속간행물번호로, 인쇄본 저널에 부여되는 고유 식별번호입니다.
eISSN Electronic ISSN. 전자 버전 저널에 부여되는 고유 식별번호입니다.
Volume 저널의 권(Volume) 번호입니다. 보통 연도별로 하나의 권이 부여됩니다.
Issue 저널의 호(Issue) 번호입니다. 한 권 내에서 여러 호로 나누어 출판되는 경우가 많습니다.
WoS Edition Web of Science의 에디션입니다. SCIE(Science Citation Index Expanded), SSCI(Social Sciences Citation Index), AHCI(Arts & Humanities Citation Index) 등으로 구분됩니다.
WoS Category Web of Science의 주제 분류 카테고리입니다. 저널과 논문이 속한 학문 분야를 나타냅니다.
JCR Year 해당 저널의 JCR(Journal Citation Reports) 지표가 산출된 연도입니다.
IF (Impact Factor) 저널 영향력 지수. 최근 2년간 발표된 논문이 해당 연도에 평균적으로 인용된 횟수를 나타냅니다. 저널의 학술적 영향력을 나타내는 대표적인 지표입니다.
JCR (%) 해당 카테고리에서 저널이 위치하는 상위 백분율입니다. 값이 낮을수록 우수한 저널임을 의미합니다 (예: 5%는 상위 5%를 의미).
FWCI Field-Weighted Citation Impact. 분야별 가중 인용 영향력 지수입니다. 논문이 받은 인용을 동일 분야, 동일 연도, 동일 문헌 유형의 평균과 비교한 값입니다. 1.0이 평균이며, 1.0보다 높으면 평균 이상의 인용을 받았음을 의미합니다.
FWCI UpdateDate FWCI 값이 마지막으로 업데이트된 날짜입니다. FWCI는 인용이 누적됨에 따라 주기적으로 업데이트됩니다.
WOS Citation Web of Science에서 집계된 해당 논문의 총 인용 횟수입니다.
SCOPUS Citation SCOPUS에서 집계된 해당 논문의 총 인용 횟수입니다.
Keywords (WoS) 저자가 논문에서 직접 지정한 키워드입니다. Web of Science에 등록된 저자 키워드 목록입니다.
KeywordsPlus (WoS) Web of Science에서 자동으로 추출한 추가 키워드입니다. 논문의 참고문헌 제목에서 자주 등장하는 단어들로 생성됩니다.
Keywords (SCOPUS) 저자가 논문에서 직접 지정한 키워드입니다. SCOPUS에 등록된 저자 키워드 목록입니다.
KeywordsPlus (SCOPUS) SCOPUS에서 자동으로 추출하거나 추가한 색인 키워드입니다.
Language 논문이 작성된 언어입니다. 대부분 English이며, 그 외 다양한 언어로 작성된 논문이 포함될 수 있습니다.
Publication Year 논문이 출판된 연도입니다.
Publication Date 논문의 정확한 출판 날짜입니다 (년-월-일 형식).
DOI Digital Object Identifier. 디지털 객체 식별자로, 논문을 고유하게 식별하는 영구적인 식별번호입니다. 이를 통해 논문의 온라인 위치를 찾을 수 있습니다.